August 01, 2015 – On July 24, 2015, the American Food and Drug Administration (FDA) approved Alirocumab (Praluent) injection, the first cholesterol-lowering treatment approved in a new class of drugs known as proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors. …

Alirocumab (Praluent): A new treatment option for patient suffering from high cholesterol Read more »